GTX (GTXI), a biopharmaceutical company, saw its loss narrow to $10.94 million or $0.15 a share for the quarter ended Jun. 30, 2014. In the last year period, the company reported a loss of $12.80 million or $0.20 a share. Analysts on average had predicted net loss of $0.12 a share.

The company has not recorded any revenues during the second quarter. While it has reported operating loss of $10.95 million, compared with operating loss of $12.82 million in the previous year period.

As on Jun. 30, 2014, the company's cash balance stood at $11.18 million, down 60.43 percent or $17.07 million from Jun. 30, 2013.

GTX has witnessed a decline in the working capital over the last one year. The company's working capital stood at $14.75 million as at Jun. 30, 2014, down $9.60 million or 39.42 percent from $24.34 million on Jun. 30, 2013. It registered an increase in current ratio to 4.98 as at Jun. 30, 2014 from 3.93 on Jun. 30, 2013.